Media ReleasesLifeHealthcare

View All LifeHealthcare News


LifeHealthcare Announces the Right to Promote Spinal Allograft Biologics Range Acquired from Australian Biotechnologies

LifeHealthcare Announces the Right to Promote Spinal Allograft Biologics Range Acquired from Australian Biotechnologies

LifeHealthcare (ASX:LHC) has today acquired the rights from Point Blank Medical to promote the Australian Biotechnologies (Aus Bio) spinal allograft biologics range and entered into a non-stocking commission only ten year distribution agreement with Aus Bio commencing 1 November 2017.

The long term partnership with Aus Bio forms a key element of LifeHeathcare’s biologics strategy, complementing LifeHealthcare’s existing synthetics biologics offering and strengthening LifeHealthcare’s spine market share in Australia. Aus Bio is a leading provider of allograft biologics in Australia and the partnership with LifeHealthcare will expand market coverage for the Allovance allograft portfolio.


For further information please download PDF attached:
Download this document